POSSIBILITIES OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING IN THE PERSONALIZATION OF SALVAGE RADIATION THERAPY IN PATIENTS WITH PROSTATE CANCER RECURRENCE

Objective. To identify the possibility of multiparametrical magnetic resonance imaging (mpMRI) in the diagnosis of clinical recurrence of prostate cancer, with the aim of optimizing salvage radiation therapy (SLT).

Material and methods. In this prospective study, the results of 89 patients with marker relapse (PSA) of prostate cancer (PCa) after radical prostatectomy was examined. mpMRI of the pelvis was performed before the SLT and 6 months later. Separately, in 44 patients, the data of dynamic contrast enhancement (DCE) with different contrast agents (gadobutrol, gadodiamide and gadoversetamide) were analyzed.

Results. According to the model of multiple linear regression, the area of the substrate of clinical recurrence is statistically significantly correlated with the PSA level (R=0.74, p<0.0008), regardless of the all type of DCE administered. The sensitivity of mpMRI in detection of clinical recurrence of PCa was 92%, specificity 81%, accuracy 88%, which was assessed by comparison with PSA level. The use of the hypofractive radiation dose to the area of clinical recurrence of PCa, detected with mpMRI, showed a more progressive drop of the marker (PSA), compared to the standard SLT scheme (McNemarre test, p<0.03). A statistically significant correlations (by the Mann–Whitney criterion with p<0.018) from the signal change in DCE after the injection of contrast agents (different types) and the substrate area.

Conclusion. mpMRI has high sensitivity, specificity and accuracy to detecting the substrate of the clinical recurrence of PCa. The use of DCE for concentration of 1.0 mmol (gadobutrol) significantly increases the reliability of detecting clinical recurrence of PCa, especially when the substrate is found to small and ultrasmall sizes. The application of DCE with the contrast agents at the concentration of 1.0 mmol (gadobutrol) prior to initiation of SLT course, helps to plan the proposed radiation exposure zone, with the aim of providing the necessary for a complete resorption of the recurrent tumor, a high tumor dose of radiation to the clinical recurrence region. 

1. Bolla M., van Poppel H., Tombal B., Vekemans K., Da Pozzo L., de Reijke T.M. et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial. Lancet. 2012; 6736 (12): 1–10. http://www.ncbi.nlm.nih.gov/pubmed/23084481 (дата обращения 23.12.2017).

2. Dal Pra A., Panje C., Zilli T., ArnoldW., Brouwer K., Garcia H. etal. Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy: a national survey on patterns of practice. Strahlenther. Onkol. 2017. DOI: 10.1007/s00066-017-1172-3

3. Ахвердиева Г.И., Панов В.О., Тюрин И.Е., Долгушин Б.И., Матвеев В.Б., Камолов Б.Ш. и др. Мультипараметрическая магнитно-резонансная томография в диагностике локального рецидива рака предстательной железы после радикальной простатэктомии. Онкоуролгия. 2015; 11 (4): 72–80. DOI: 10.17 650/1726-9776-2015-11-4-72-80 [Akhverdieva G.I., Panov V.O., TyurinI.E., Dolgushin B.I., Matveev V.B., Kamolov B.Sh. et al. Multiparametric magnetic resonance tomography in the diagnosis of local recurrence of prostatate cancer after radical prostatectomy. Cancer Urology.2015; 11 (4): 72–80. DOI: 10.17 650/1726-9776-2015-11-472-80 (in Russ.).]

4. Swanson G.P., Hussey M.A., Tangen C.M., Chin J., Messing E., Canby-Hagino E. et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J. Clin. Oncol. 2007; 25(16): 2225–9.

5. Ткачев С.И., Матвеев В.Б., БулычкинП.В. «Спасительная» лучевая терапия после радикальной простатэктомии с использованием последних достижений в радиационной онкологии. Российский онкологический журнал. 2016; 21 (1): 26–31. DOI: 10.4261/1305-3825.DIR.3605-10.1 [Tkachev S.I., Matveev V.B., BulychkinP.V. Salvage radiation therapy after radical prostatectomy using the latest advances in radiation oncology. Russian Journal of Oncology. 2016; 21 (1): 26–31. DOI: 10.4261/1305-3825.DIR. 3605-10.1 (in Russ.).]

6. Song C., Kang H.-C., Kim J.-S., Eom K.-Y., Kim I.A., Chung J.-B. elal. Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy. Strahlenther. Onkol. 2015; 191(10): 801–9.

7. Bernard J.R., Buskirk S.J., HeckmanM.G., Diehl N.N., Ko S.J., Macdonald O.K. et al. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int. J. Radiat. Oncol. Biol. Phys. 2010; 76(3): 735–40.

8. Siegmann A., Bottke D., Faehndrich J., Lohm G., Miller K., Bartkowiak D. et al. Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progressionfree survival: results of a retrospective study. Strahlenth. Onkol. 2011; 187(8): 467–72.

9. Amzalag G., Rager O., Tabouret-Viaud C., Wissmeyer M., Sfakianaki E., De PerrotT. et al. Target definition in salvage radiotherapy for recurrent prostate cancer: the role of advanced molecular imaging. Front. Oncol. 2016; 6.

10. Cirillo S., Petracchini M., Scotti L., Gallo T., Macera A., Bona M.C. etal. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur. Radiol. 2009; 19 (3): 761–9.

11. Boonsirikamchai P., Kaur H., Kuban D.A., Jackson E., Hou P., ChoiH. Use of maximum slope images generated from dynamic contrast-enhanced MRI to detect locally recurrent prostate carcinoma after prostatectomy: a practical approach. Am. J. Roentgenol. 2012; 198(3).

12. Wassberg C., Akin O., Vargas H.A., Shukla-Dave A., Zhang J., Hricak H.The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. Am. J. Roentgenol. 2012; 199(2): 360–6.

13. Коссов Ф.А., Черняев В.А., Ахвердиева Г.И., Камолов Б.Ш., Абдулин И.И. Роль и значение мультипараметрической магнитно-резонансной томографии в диагностике рака предстательной железы. Онкоурология. 2017;13 (1): 122–33. DOI: 10.17 650/ 1726-9776-2017-13-1-122-133 [Kossov F.A., Chernyaev V.A., Akhverdieva G.I., Kamolov B.Sh., Abdulin I.I. Role and significance of multiparametric magnetic resonance imaging in the diagnosis of prostate cancer. Cancer Urology. 2017; 13 (1): 122–33. DOI: 10.17 650/1726-9776-2017-13-1-122-133 (in Russ.).]

14. Röthke M., Blondin D., SchlemmerH.-P., Franiel T. PI-RADS classification: structured reporting for MRI of the prostate. Rofo. 2013; 185 (3): 253–61. http://www.ncbi.nlm.nih.gov/pubmed/23404430 (дата обращения: 23.12.2017).

15. Kitajima K., Murphy R.C., Nathan M.A., Froemming A.T., HagenC.E., Takahashi N. et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11CCholine PET/CT with pelvic multiparametric MR imaging with endorectal coil. J. Nucl. Med.2014; 55 (2): 223–32.

16. Ахвердиева Г.И., Санай Э.Б., Панов В.О., Тюрин И.Е., Матвеев В.Б., Шимановский Н.Л. Роль искусственного контрастирования при МРТ-диагностике рака предстательной железы (обзор литературы). Медицинская визуализация. 2012; 1: 92–101. [Akhverdieva G.I., Sanay E.B., Panov V.O., Tyurin I.E., Matveev V.B., Shimanovskiy N.L. Contrast enhancement in MRI diagnostics of prostate cancer. Literature review. Medical Visualization. 2012; 1: 92–101 (in Russ.).]

17. Трофимова Т.Н., ШимановскийН.Л. Новые возможности улучшения дифференциальной диагностики инсульта и опухолей головного мозга с помощью МРТ с контрастным усилением гадовистом. Лучевая диагностика и терапия. 2016; 2: 93–109. DOI: 10.22328/2079-5343-2016-2-93-109 [Trofimova T.N., Shimanovskiy N.L. New opportunities to improve differential diagnosis of stroke and brain tumors with MRI with contrast enhancement of gadovist. Diagnostic Radiology and Radiotherapy. 2016; 2: 93–109. DOI: 10.22328/2079-5343-2016-2-93-109 (in Russ.).]

18. Шимановский Н.Л., Наполов Ю.К. Применение магнитно-резонансной визуализации с контрастным усилением для диагностики заболеваний мочевыделительной системы. I. Диагностика морфологических и функциональных нарушений. Магнитнорезонансная ангиография почек. Урология. 2006; 6: 93–5. [ShimanovskyN.L., Napolov Yu.K. MRI visualization with contrast magnification for diagnosis of urinary diseases. I. Diagnosis of morphological and functional disorders. MR angiography of the kidneys. Urologia. 2006; 6: 93–5 (in Russ.).]

19. Харламов В.Г., Кулаков В.Н., Липенгольц А.А., Шимановский Н.Л. Стабильность гадолинийсодержащих магнитно-резонансных контрастных средств в присутствии ионов цинка и кальция в различных средах. Вестник Российского государственного медицинского университета. 2016; 1: 73–8. [Kharlamov V.G., Kulakov V.N., Lipengol’ts A.A., Shimanovskii N.L. Stability of gadolinium-containing magnetic resonance contrast agents in the presence of zinc and calcium ions in various media. Bulletin of Russian State Medical University. 2016; 1: 73–8 (in Russ.).]

20. Панов В.О., Шимановский Н.Л. Диагностическая эффективность и безопасность макроциклических гадолинийсодержащих магнитно-резонансных контрастных средств. Вестник рентгенологии и радиологии. 2017; 98(3): 159–66. [Panov V.O., Shimanovskiy N.L. The diagnostic efficacy and safety of macrocyclic gadolinium-containing magnetic resonance contrast agents. Vestnik Rentgenologii i Radiologii (Russian Journal of Radiology). 2017; 98(3): 159–66 (inRuss.).]